nav-left cat-right

AstraZeneca, Bristol-Myers grant for diabetes research

AstraZeneca’s ($AZN) and Bristol-Myers Squibb’s ($BMY) U.S. Diabetes Alliance is giving a three-year, $5 million grant to the American Diabetes Association’s Pathway to Stop Diabetes program. The Pathway initiative provides up to $1.6 million in support for 5 to 7 years to selected investigators to help fund research relevant to any diabetes type, diabetes-related disease state or diabetes complication.